Expression and Clinical Significance of Soluble B7-H3 in Patient with Secondary Hemophagocytic Lymphohistiocytosis.
10.19746/j.cnki.issn.1009-2137.2020.03.048
- Author:
Xin LYU
1
;
Yue WANG
2
;
Ling-Ling WANG
3
;
Guang-Li YIN
3
;
Ling-Ling LIU
3
;
Li-Min DUAN
4
;
Tian TIAN
4
;
Ji XU
4
;
Hong-Xia QIU
5
Author Information
1. Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing 210029, Jiangsu province, China,Department of Hematology, Linyi Central Hosiptal, Yishui 276400, Shandong Province, China.
2. Department of Hematology, Linyi Central Hosiptal, Yishui 276400, Shandong Province, China.
3. Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing 210029, Jiangsu province, China.
4. Department of Geriatric Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital. Nanjing 210029, Jiangsu province, China.
5. Department of Geriatric Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital. Nanjing 210029, Jiangsu province, China,E-mail:qhx9805@126.com.
- Publication Type:Journal Article
- MeSH:
Enzyme-Linked Immunosorbent Assay;
Humans;
Lymphohistiocytosis, Hemophagocytic;
Lymphoma;
ROC Curve
- From:
Journal of Experimental Hematology
2020;28(3):1006-1011
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the expression and clinical significance of soluble B7-H3 (sB7-H3) in patients with secondary hemophagocytic lymphohistiocytosis (sHLH).
METHODS:The plasma samples of 85 newly diagnosed sHLH patients from December 2012 to April 2018 were collected. The patients were divided into lymphoma-related HLH（LHLH）group and infection-related HLH（IHLH）group. The expression of sB7-H3 in plasma was detected by ELISA, and the clinical data were collected for analysis. Fifteen healthy people were chosen as control group.
RESULTS:The expression level of sB7-H3 in lymphoma-related HLH and infection-related HLH group significant increased as compared with the control group, (P＜0.05), and the expression level of sB7-H3 in lymphoma-related HLH group was significant higher than that in infection-related HLH group [(35.75± 9.90) vs (28.70±8.95) ng/ml)] (P＜0.001). There were no significant statistical difference in the expression of some clinical factors (including age, fever, splenomegaly, ANC, Plt, FIB, calcium ion, serum albumin, LDH, serum ferritin, sCD25) in lymphoma-related HLH and infection-related HLH group (P＞0.05). The evaluation of expression and significance of sB7-H3 in sHLH by using ROC curve, showed that the area under ROC curve comparison of patients in lymphoma-related HLH group and infection-related HLH group was 0.718 (95% CI 0.610-0.810) (P=0.0002), and predicting the sensitivity and specificity of the lymphoma-related HLH patients were 77.36% and 59.38%, respectively. The best cut-off value of patients in sB7-H3 was 29.81 ng/ml, the overall survival time of sB7-H3 high-expression group (≥29.81 ng/ml) was significant shorter than that in low-expression group (＜29.81 ng/ml) (24 vs 440 d) (P＜0.001). The clinical factors affecting the survival status of sHLH patients were neutrophils, albumin, serum ferritin, serum calcium ions and sB7-H3 levels.
CONCLUSION:sB7-H3 associates with poor prognosis of sHLH patients, and may be involved in disease progression.
